US 12,454,540 B2
Prodrugs of L-BHDU and methods of treating viral infections
Uma Sharan Singh, Athens, GA (US); and Chung Chu, Duluth, GA (US)
Assigned to UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US); and ANTEROGEN CO., LTD, Seoul (KR)
Filed by UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US); and Anterogen Co., Ltd, Seoul (KR)
Filed on Feb. 7, 2024, as Appl. No. 18/435,109.
Application 18/435,109 is a continuation of application No. 17/976,407, filed on Oct. 28, 2022, granted, now 11,945,833.
Claims priority of provisional application 63/273,403, filed on Oct. 29, 2021.
Prior Publication US 2024/0199662 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61P 31/22 (2006.01); C07F 9/6558 (2006.01)
CPC C07F 9/65586 (2013.01) [A61K 31/675 (2013.01); A61K 45/06 (2013.01); A61P 31/22 (2018.01)] 37 Claims
 
1. A prodrug compound of L-BHDU according to the chemical structure I:

OG Complex Work Unit Chemistry
Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group;
R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group;
R1a is independently a C12-C22 alkyl group;
R2a is independently a C1-C12 alkyl group;
Each j is independently 1-6;
Each k is 0 or 1;
Each n is independently 2-4; or
A pharmaceutically acceptable salt thereof.